» Articles » PMID: 30480162

Validation of a Claims-based Algorithm Identifying Eligible Study Subjects in the ADAPTABLE Pragmatic Clinical Trial

Overview
Date 2018 Nov 28
PMID 30480162
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Validate an algorithm that uses administrative claims data to identify eligible study subjects for the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) pragmatic clinical trial (PCT).

Materials And Methods: This study used medical records from a random sample of patients identified as eligible for the ADAPTABLE trial. The inclusion criteria for ADAPTABLE were a history of acute myocardial infarction (AMI) or percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), or other coronary artery disease (CAD), plus at least one of several risk-enrichment factors. Exclusion criteria included a history of bleeding disorders or aspirin allergy. Using a claims-based algorithm, based on International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) and 10th Edition (ICD-10) codes and Current Procedural Terminology (CPT) codes, we identified patients eligible for the PCT. The primary outcome was the positive predictive value (PPV) of the identification algorithm: the proportion of sampled patients whose medical records confirmed their ADAPTABLE study eligibility. Exact 95% confidence limits for binomial random variables were calculated for the PPV estimates.

Results: Of the 185 patients whose medical records were reviewed, 168 (90.8%; 95% Confidence Interval: 85.7%, 94.6%) were confirmed study eligible. This proportion did not differ between patients identified with codes for AMI and patients identified with codes for PCI or CABG.

Conclusion: The estimated PPV was similar to those in claims-based identification of drug safety surveillance events, indicating that administrative claims data can accurately identify study-eligible subjects for pragmatic clinical trials.

Citing Articles

The Healthcare Integrated Research Database (HIRD) as a Real-World Data Source for Pharmacoepidemiologic Research.

Barron J, Willey V, Doherty B, Tunceli O, Waltz C, Grabner M Pharmacoepidemiol Drug Saf. 2025; 34(2):e70110.

PMID: 39909722 PMC: 11798679. DOI: 10.1002/pds.70110.


Long-Term Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention Among Medicare Beneficiaries.

Almarzooq Z, Tamez H, Wang Y, Curtis J, Kirtane A, Secemsky E J Soc Cardiovasc Angiogr Interv. 2024; 2(2):100584.

PMID: 39129810 PMC: 11307545. DOI: 10.1016/j.jscai.2023.100584.


Pragmatic guidance for embedding pragmatic clinical trials in health plans: Large simple trials aren't so simple.

Cocoros N, Gurwitz J, Cziraky M, Granger C, Harkins T, Haynes K Clin Trials. 2023; 20(4):416-424.

PMID: 37322894 PMC: 10363182. DOI: 10.1177/17407745231160459.


Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.

Luo J, Feldman R, Callaway Kim K, Rothenberger S, Korytkowski M, Hernandez I JAMA Netw Open. 2023; 6(6):e2317886.

PMID: 37307000 PMC: 10261995. DOI: 10.1001/jamanetworkopen.2023.17886.


Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019.

Zheutlin A, Derington C, Herrick J, Rosenson R, Poudel B, Safford M Circ Cardiovasc Qual Outcomes. 2022; 15(12):e008861.

PMID: 36252093 PMC: 10680021. DOI: 10.1161/CIRCOUTCOMES.121.008861.


References
1.
Hall H, de Lemos J, Enriquez J, McGuire D, Peng S, Alexander K . Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014; 7(5):701-7. DOI: 10.1161/CIRCOUTCOMES.113.000822. View

2.
Corley D, Feigelson H, Lieu T, McGlynn E . Building Data Infrastructure to Evaluate and Improve Quality: PCORnet. J Oncol Pract. 2015; 11(3):204-6. PMC: 4438109. DOI: 10.1200/JOP.2014.003194. View

3.
Bui C, Kaye J, Castellsague J, Calingaert B, McQuay L, Riera-Guardia N . Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users. Curr Drug Saf. 2013; 9(1):23-8. DOI: 10.2174/15748863113086660051. View

4.
Johnston A, Jones W, Hernandez A . The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. Curr Cardiol Rep. 2016; 18(8):81. DOI: 10.1007/s11886-016-0749-2. View

5.
Lantos J, Wendler D, Septimus E, Wahba S, Madigan R, Bliss G . Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials. Clin Trials. 2015; 12(5):485-93. PMC: 4703320. DOI: 10.1177/1740774515597687. View